The estimated Net Worth of Jacquelyn L Sumer is at least $27.3 Tausend dollars as of 21 December 2023. Ms Sumer owns over 1,400 units of Genocea Biosciences Inc stock worth over $0 and over the last 4 years she sold GNCA stock worth over $27,307.
Ms has made over 7 trades of the Genocea Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 1,400 units of GNCA stock worth $11,900 on 21 December 2023.
The largest trade she's ever made was selling 2,500 units of Genocea Biosciences Inc stock on 1 June 2022 worth over $150. On average, Ms trades about 413 units every 44 days since 2021. As of 21 December 2023 she still owns at least 44,133 units of Genocea Biosciences Inc stock.
You can see the complete history of Ms Sumer stock trades at the bottom of the page.
Jacquelyn L. Sumer is the Chief Legal & Compliance Officer at Genocea Biosciences Inc.
Jacquelyn's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: